Arrowhead Research Corporation (NASDAQ: ARWR) today announced the publication of data from Ablaris Therapeutics, Inc.’s lead drug candidate, Adipotide™, demonstrating weight loss and reduction in body mass index and abdominal circumference in obese rhesus monkeys.
The findings reveal a promising pharmacological way to substantially reduce accumulated fat in non-human primates, and potentially humans. Unlike most anti-obesity drugs, which attempt to control appetite or prevent absorption of dietary fat, Adipotide directly attacks subcutaneous and visceral fat.
Dr. Christopher Anzalone, President and Chief Executive Officer of Arrowhead, commented:
“Safely and effectively treating the obesity epidemic is one of the great unmet needs in medicine today. This study is a radical step forward for both Ablaris’ technology and the treatment of obesity. It is uncommon for an obesity treatment to be successfully translated from rodent studies to non-human primates. Ablaris’ approach is distinguished from others in the field by its unique mode of action. By acting directly on the vasculature that supports fat tissue rather than on the brain, we believe that we can avoid many of the safety issues that have blocked other anti-obesity drug candidates. We are extremely encouraged by the results achieved to date with Adipotide and believe that Ablaris’ unique technology offers a significant advantage to combating obesity as we prepare to enter the clinic in the near-term.”
ARWR stock posted gain of 40.19% by closing at $.75 withing 5,817,568 shares in daily volume. 44,105 shares has been traded after-hours with last trade at $.85.
Arrowhead Research Corporation
225 South Lake Avenue, 3rd Floor
Pasadena, CA 91101
Tel: (626) 304-3400
Fax: (626) 304-3401
Arrowhead Research Corporation is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering. Arrowhead is currently focused on the preclinical and clinical development of therapeutics for the treatment of cancer and obesity, as well as healing wounded or diseased tissue. Arrowhead’s partners include some of the most well-recognized and inventive leaders in nanoscience.
Arrowhead’s current portfolio of subsidiaries includes majority holdings in Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing, and Ablaris Therapeutics, an anti-obesity therapeutics company. The Company also holds minority interest in Nanotope, a regenerative medicine company, and Leonardo Biosciences, a next generation drug delivery company initially targeting treatment for cancer.